About iCellate

iCellate is a Swedish, medical technology company founded in 2011 and is based in Stockholm. iCellate develops products in the areas of cancer diagnosis and individual cancer treatment. The technology is based on research from the Karolinska Institute in collaboration with the Karolinska University Hospital and the Royal Institute of Technology in Stockholm.

The company is today part of the Uppsala Innovation Center (UIC) and has over the years received several awards from both scientific institutions and private companies.

The Management Team

Pelle Redare (CEO) brings a wealth of experience from the Medtech business where he has worked more than 20 years for both small and large companies, for example Siemens, Radi Medical and St Jude Medical. As CEO for iCellate, Pelle combines his great experiences from CEO positions in larger companies and background from running small start-up companies.

Christer Ericsson, PhD, (CSO) is an award-winning cancer biologist and a specialist in clinical sample handling. Christer Ericsson has published numerous scientific papers in “Cell” and other respected international journals and monographs in cancer biology. He has held research positions at the Salk Institute in San Diego, CA, the Karolinska Institute in Stockholm, Sweden and at the State University of New York in Buffalo, New York.

Iohn Ryott (COO) has worked both nationally and internationally in a number different Medtech companies, ranging from small to large size. Iohn has worked with sales and marketing in Europe, US and Asia and has gathered extensive knowledge in sales execution, negotiation and leadership. Iohn plays a vital role in the commercialization phase of iCellate.

Åsa Rosenquist (VP R&D) assumed the position as head of iCellate's research department and lab operations in 2019. Åsa comes most recently from XSpray Pharma and, in addition to working at Karolinska Institute and the Public Health Authority, has worked primarily with drug development at Medivir. Åsa's knowledge of leading employees combined with many years of experience in lab work and project/product development make her a very important part of iCellate's future team development.

Francisca Lameiras (Quality Director) joined iCellate in 2017. Francisca holds a PhD degree in Metabolic Engineering from Delft University of Technology (The Netherlands) and is a results-driven and dynamic scientist. Francisca started her carrier at iCellate as Head of Lab and assumed in 2020 the role as head of Quality Assurance and Regulatory Affairs. With her knowledge in both R&D and Quality she is a vital part of iCellate continuous development.

Board of Directors

Ulf Tossman (Chairman of the Board) 
Ulf has extensive experience from the Life Science sector from executive operational positions as well as board member functions. Please see linkedin.com for more details.

Harald Blegen (Board member)
Harald is senior consultant at the surgery department at Karolinska University Hospital and was previously head of Tema cancer. Harald contributes to the board work with his experiences and clinical contacts.
Please see linkedin.com for more details.

Iohn Ryott (Board member)
See above.

Mari Vattekar Markman (Board member)
Mari has a background as an interest rate analyst at DNB Markets but also in interior design in her own company.
Please read more at linkedin.com for more details.

Johan Markman (Deputy board member)
Deputy Chairman of the Board at Camfil AB
Please see www.camfil.com for more details.


Scientific research

White Papers

Case Studies

Notable awards and grants


iCellate awarded Horizon 2020 grant to enable launch of CellMate® in the European market in collaboration with QIAGEN and UKSH.

Comp. diagnostics

Together with the Swiss pharmaceutical company Elthera, iCellate received Eurostars to develop a companion diagnostic in pancreatic cancer.

R&D Collaboration

iCellate entered strategic partnerships with some key affiliates, leading to new discoveries in cell detection automation and the service CellMate®.


iCellate was awarded the ”Vinn verifiering” by Vinnova that resulted in early verification of the CTC isolation technique.


2021Fast-track to innovation - CellMate®Horizon 2020
2020Companion diagnostics developmentEurostars
2018EIT Success storyEIT Health
2016Headstart & Proof of Concept ProgrammeEIT Health
2016Styra cancerbehandlingAFA Försäkring
2013-2016EurostarsEU commission
2012-2015BIO-X supportUppsala BIO
2012-2014Research collaborationRoche
2012-2013IPR analysis awardSISP
2011-2012Vinn Verifiering VINNOVA
2011Starget 3SA (scientific prize)Karolinska Institute
2011Business development competition (first prize)STING Startup
2011Fokus verifieringInnovationsbron
2011Business plan competition (finalist)Venture Cup Öst